摘要
目的:探讨高选择性与非选择性β-受体阻断剂治疗慢性充血性心力衰竭的疗效及安全性是否有差异。方法:将108例非瓣膜性慢性充血性心力衰竭患者随机分为两组,接受非选择性β-受体阻断剂(卡维地洛)治疗组和接受高选择性β-受体阻断剂(美托洛尔)治疗组,对比治疗前后的心功能,LVEF,LVFS,血压,心率及副作用。结果:卡维地洛组治疗慢性充血性心力衰竭总有效率为96.3%,高于美托洛尔组的83.3%,差异有显著性(P<0.05),美托洛尔组引起心衰加重及房室传导阻滞例数比卡维地洛组多见。结论:高选择性与非选择性β-受体阻断剂在治疗慢性充血性心力衰竭中实际疗效有差别。在不良反应上,高选择性β-受体阻断剂诱发心衰加重及房室传导阻滞可能性较高。
Objective ：To study the efficacy and safety of non - selective and high - selective β- blocker on chronic congestive heart failure（CHD）. Methods： 108 patients with non- valve CHD were divided into 2 groups, contrast group receiving non - selectiveβ- blocker Carvedilol, studying group high - selective Metoprolol. The heart function, LVEF, LVFS, BP, heart rate and adverse reaction were compared before and after treatment. Results： The total efficacy ratio in contrast group is 96.3%, that in studying group 83.3%. There is a significant difference （ P 〈 0.05）. The aggravation of heart failure and AV blocker in studying group occurred more than that in contrast group. Conclusions： There is difference in efficacy for Carvedilol and Metoprolol. The high- seleclive drugs have much more adverse reactions in aggravation of heart failure and AV blocker than non - selective drugs.
出处
《中国民康医学》
2006年第3期113-115,共3页
Medical Journal of Chinese People’s Health
